EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, RCKT: Rocket Pharmaceuticals Inc

24 Oct 25 15:59
LAST:

3.840

CHANGE:
 0.11		OPEN:
3.830		HIGH:
3.900		ASK:
0.000		VOLUME:
1.09M
CHG(%):
2.94		PREV:
3.740		LOW:
3.800		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
24 Oct 253.8303.9003.8003.8501.24M
23 Oct 253.8003.8003.6653.7402.13M
22 Oct 253.9703.9703.6853.8002.07M
21 Oct 254.0204.0403.8103.9801.4M
20 Oct 253.8004.0653.7504.0002.41M
17 Oct 253.9203.9393.6303.7102.89M
16 Oct 254.2404.3353.9854.0002.59M
15 Oct 254.2804.5094.0504.2407.3M
14 Oct 253.9204.3403.8234.2709.69M
13 Oct 253.5003.5743.4103.4702.23M

COMPANY PROFILE

Name:Rocket Pharmaceuticals Inc
About:Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases in the United States. It develops vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage. It also develops vivo lentiviral (LV) programs, which include programs for Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201); Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102); and Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301). It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; REGENXBIO, Inc.; and Temple University. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.
Sector:Healthcare
Industry:Biotechnology
Address:9 Cedarbrook Drive, Cranbury, NJ, United States, 08512
Website:https://www.rocketpharma.com
CUSIP:77313F106
CIK:0001281895
ISIN:US77313F1066
FIGI:BBG000WG3567
LEI:549300R7VV82YUIN4Y93

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:3.870.9%
MA10:3.911.7%
MA20:3.606.8%
MA50:3.4013.0%
MA100:3.1820.9%
MA200:5.5544.5%
STO9:17.52 
STO14:51.85
RSI14:61.59 
WPR14:-37.17
MTM14:0.71
ROC14:0.23 
ATR:0.33 
Week High:4.075.9%
Week Low:3.635.8%
Month High:4.5117.4%
Month Low:3.1044.5%
Year High:18.17373.2%
Year Low:2.1975.3%
Volatility:7.08 

RECENT SPLITS

Date Ratio
05 Jan 20181-4